The deal is modest in size for GSK ($97B market cap) and the asset is pre-clinical, so near-term stock impact is limited. Monitor for phase I data readouts in 2027 and any updates on milestone payments or regulatory developments.
GSK drugs
GSK drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Sep 15 $50.01entry
- T+1 · 2mo ago +0.45%α +0.12% · $50.23
- T+5 · 8w ago +0.42%α −0.40% · $50.22
- T+20 · 5w ago −7.48%α −10.46% · $46.27
- T+44 · todayOpen
- T+60 · in 22d Pending
Price Chart
How similar events traded
Executive Summary
GSK announced an agreement to acquire a potential best-in-class trispecific T cell-engager (TCE) for multiple myeloma from privately held Chimagen Biosciences. The deal has a total potential value of up to $750 million, including an upfront fee and success-based milestone payments, with the programme expected to enter phase I trials in 2027. This acquisition builds on GSK's existing relationship with Chimagen and aligns with its strategy to expand its blood cancer portfolio, though the asset is pre-clinical and carries development risk.
Key Facts
- GSK entered an agreement to acquire a trispecific T cell-engager (TCE) for multiple myeloma from Chimagen Biosciences.
- The total potential value of the agreement is up to $750 million, including an upfront fee and success-based milestone payments.
- The programme is expected to enter phase I clinical trials in 2027.
- The US TCE market for multiple myeloma is expected to exceed $10 billion by 2032 (external forecast).
- This deal follows a previous agreement between GSK and Chimagen for CMG1A46, a clinical-stage dual CD19 and CD20-targeted TCE.
Financial Impact
Total potential deal value up to $750 million, with upfront fee and success-based milestones; no specific upfront amount disclosed.
Risk Factors
- Pre-clinical asset carries high development risk; phase I trials may fail to demonstrate differentiated efficacy or safety.
- Upfront fee and milestone payments could pressure cash flow if the programme underperforms.
- Competition in the multiple myeloma TCE space is intense, with existing approved therapies.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-008359 |
| Document: 0001654954-26-008359-index-headers.html | 0001654954-26-008359 |
| Document: 0001654954-26-008359-index.html | 0001654954-26-008359 |
| Document: 0001654954-26-008359.txt | 0001654954-26-008359 |
Track record
64 reports on GSK
9 of 18 bullish or bearish reports moved the stock their way by T+20. Best: +9.35% at T+60 after the Jul 17, 2026 report. 15 of 21 went positive at some point.
Filters
- Nov 13, 20263d ago 6-K Neutral 4/10 Entry $50.45 Now $50.41 −0.08% settles Dec 14
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $50.64 Now $50.41 −0.45% settles Dec 11
- Nov 6, 202610d ago 6-K Neutral 1/10 Entry $50.33 Now $50.41 +0.16% settles Dec 7
- Nov 2, 202614d ago 6-K Neutral 1/10 Entry $49.13 Now $50.41 +2.61% settles Dec 1
- Oct 28, 202619d ago 6-K Neutral 5/10 Entry $48.74 Now $50.41 +3.43% settles Nov 25
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Neutral 1/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Neutral 4/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 21, 202626d ago 6-K Bullish 7/10 Entry $50.02 Now $50.41 +0.78% settles Nov 18
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers